Sodium-glucose cotransporter 2 (SGLT2) inhibitors have shown impressive consistency of class benefit with regard to improving cardiovascular outcomes in high-risk individuals across age, sex, and ethnicity groups, in a new meta-analysis.

In a meta-analysis of 10 randomized clinical trials, investigators noted that the primary outcome of cardiovascular death or hospitalization for heart failure occurred in 8.10% patients who received SGLT2 inhibitors compared to 11.56% receiving placebo. This represents a significant difference with odds ratio of 0.67 (P < .001). Both of the individual outcomes were found to be lower with SGLT2 inhibitor use, with a number needed to treat of 5.7 (P < .001). Those who received SGLT2 inhibitors had significantly lower rates of major adverse cardiovascular events (death due to cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke), occurring in 9.82% vs. 10.22% (odds ratio 0.90) (P = .03).

The findings are published online in JAMA Network Open… (Medscape)